Jack in the Box Inc. filings document the company’s quick-service restaurant operations, periodic financial results and material events affecting its public-company governance and capital structure. Recent Form 8-K disclosures cover earnings releases, same-store sales information, discontinued operations following the completed Del Taco sale, and material agreements.
The company’s regulatory record also includes stockholder-rights and governance disclosures, including amendments and ratification of a Stockholder Protection Rights Agreement, annual meeting voting results, board appointments, director retirements, committee assignments and nomination cooperation arrangements. These filings describe how corporate actions affect security-holder rights, board composition and shareholder-control provisions.
Jack in the Box Inc. (NASDAQ: JACK) has adopted a Stockholder Protection Rights Agreement—commonly known as a poison pill—effective July 1, 2025. Shareholders of record on July 14, 2025 will receive a dividend of one Right for each common share. Each Right becomes exercisable only after a Separation Time, triggered when any person or group acquires or commences a tender offer for 12.5 % or more of the company’s outstanding shares. Upon activation, a Right allows the holder to buy, for $90, one-one-thousandth of a share of Participating Preferred Stock—economically equivalent to diluting the acquirer by giving other investors the right to purchase stock at an effective 50 % discount.
Key terms
- Exercise price: $90 per Right.
- Expiration: July 1, 2026, extendable to July 1, 2028 if ratified by stockholders.
- Redemption: Board may redeem all Rights at $0.001 per Right any time before a Flip-in Date.
- Flip-in threshold: 12.5 % beneficial ownership.
- Flip-over protection: Ensures equivalent value if a merger or major asset sale occurs after an acquirer controls ≥50 % of shares.
The plan is administered by Computershare Trust Company, N.A. as Rights Agent. Management argues that the Rights protect shareholders by encouraging anyone seeking control to negotiate directly with the Board. However, governance-focused investors often view poison pills as potential entrenchment tools that can block takeover premiums. The adoption follows no announced bid, suggesting a pre-emptive defense amid elevated M&A activity in the fast-food sector. No financial results were disclosed in this 8-K.